Analyst firms · Citigroup · IONS

Citigroup IONS price target and rating history

Ionis Pharmaceuticals Inc. (IONS) · Health Care

Citigroup rates Ionis Pharmaceuticals Inc. (IONS) Buy with a $115 price target, as of its latest action on May 19, 2026. It has published 4 rating actions on IONS since March 2022, including 2 upgrades and 0 downgrades. Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50. Citigroup's $115 is 16% above that.

Current rating

Buy

Price target

$115

Median target, all firms

$99.50

Actions on IONS

4

Citigroup price target on IONS

Every Citigroup rating on IONS

• May 19, 2026
  InitiateCitigroup starts coverage at Buy, price target $115
• Jul 31, 2023
  UpgradeCitigroup upgrades to Buy from Neutral, price target $36 to $60
• May 4, 2023
  UpgradeCitigroup upgrades to Neutral from Sell, price target $30 to $36
• Mar 1, 2022
  InitiateCitigroup starts coverage at Sell, price target $26

How other firms rate IONS

Each firm's latest rating and stated target in the last 12 months.

Questions about Citigroup and IONS

What is Citigroup's price target for IONS?

Citigroup's latest stated price target for Ionis Pharmaceuticals Inc. (IONS) is $115, from its action on May 19, 2026.

What is Citigroup's rating on IONS?

Citigroup rates IONS Buy, a bullish rating, as of May 19, 2026.

When did Citigroup last change its view on IONS?

On May 19, 2026, Citigroup starts coverage at Buy, price target $115.

How does Citigroup's IONS target compare with other analysts?

Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50. Citigroup's $115 is 16% above that.

More IONS rating histories

• BMO Capital Markets5
• Morgan Stanley5
• Leerink Partners6
• BofA Securities3

All Citigroup ratingsIONS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.